Pristimerin Inhibits LPS-Triggered Neurotoxicity in BV-2 Microglia Cells Through Modulating IRAK1/TRAF6/TAK1-Mediated...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Microglia are key in brain inflammation but hyperactivation contributes to neurodegeneration.
• Pristimerin, a triterpenoid, has known anti-inflammatory properties.
• The mechanism of pristimerin against LPS-induced neurotoxicity in microglia is unclear.

Purpose of the Study:

• To investigate pristimerin's effects on lipopolysaccharide (LPS)-induced neurotoxicity in BV-2 microglial cells.
• To elucidate the molecular pathways involved in pristimerin's neuroprotective action.

Main Methods:

• BV-2 microglial cell cultures were stimulated with LPS.
• Pristimerin's effects on inflammatory markers (RANTES, TGF-β1, IL-6, TNF-α, NO) and microglial migration were assessed.
• Neuronal cell death was evaluated using conditioned medium from LPS-activated microglia.
• Intracellular signaling pathways (TRAF6, IRAK1, TAK1, NF-κB, JNK/AP-1) were analyzed.

Main Results:

• Pristimerin significantly suppressed the release of RANTES, TGF-β1, IL-6, TNF-α, and NO.
• Pristimerin inhibited microglial migration and protected PC12 cells from LPS-induced neurotoxicity.
• Pristimerin reduced TRAF6/IRAK1 expression and interaction, limiting TAK1 activation.
• Pristimerin inhibited IKKα/β/NF-κB and MKK7/JNK/AP-1 signaling pathways.

Conclusions:

• Pristimerin exhibits anti-neurotoxicity effects by inhibiting microglial activation and inflammatory responses.
• The mechanism involves suppressing TRAF6/IRAK1/TAK1 interaction and downstream NF-κB and JNK/AP-1 pathways.
• Pristimerin shows potential as a therapeutic agent for neurodegenerative diseases linked to microglial hyperactivation.